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Rationale: Stimulation of β3-adrenoreceptors (β3-AR) blunts contractility and improves chronic left ventric-
ular function in hypertrophied and failing hearts in a neuronal nitric oxide synthase (nNOS) dependent man-
ner. nNOS can be regulated by post-translational modiﬁcation of stimulatory phosphorylation residue
Ser1412 and inhibitory residue Ser847. However, the role of phosphorylation of these residues in
cardiomyocytes and β3-AR protective signaling has yet to be explored.
Objective: We tested the hypothesis that β3-AR regulation of myocyte stress requires changes in nNOS acti-
vation mediated by differential nNOS phosphorylation.
Methods and results: Endothelin (ET-1) or norepinephrine induced hypertrophy in rat neonatal ventricular
cardiomyocytes (NRVMs) was accompanied by increased β3-AR gene expression. Co-administration of the
β3-AR agonist BRL-37433 (BRL) reduced cell size and reactive oxygen species (ROS) generation, while
augmenting NOS activity. BRL-dependent augmentation of NOS activity and ROS suppression due to NE
were blocked by inhibiting nNOS (L-VNIO). BRL augmented nNOS phosphorylation at Ser1412 and dephos-
phorylation at Ser847. Cells expressing constitutively dephosphorylated Ser1412A or phosphorylated
Ser847D nNOS mutants displayed reduced nNOS activity and a lack of BRL modulation. BRL also failed to de-
press ROS from NE in cells with nNOS-Ser847D. Inhibiting Akt decreased BRL-induced nNOS-Ser1412 phos-
phorylation and NOS activation, whereas Gi/o blockade blocked BRL-regulation of both post-translational
modiﬁcations, preventing enhancement of NOS activity and ROS reduction. BRL resulted in near complete de-
phosphorylation of Ser847 and a moderate rise in Ser1412 phosphorylation in mouse myocardium exposed
to chronic pressure-overload.
Conclusion: β3-AR regulatesmyocardial NOS activity andROSvia activationof nNOS involving reciprocal changes in
phosphorylation at two regulatory sites. These data identify a novel and potent anti-oxidant and anti-hypertrophic
pathway due to nNOS post-translational modiﬁcation that is coupled to β3-AR receptor stimulation.© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.School of Medicine, Division of
, MD 21045, USA. Tel.: +1 410
td. Open access under CC BY-NC-ND li1. Introduction
Sustained sympathetic activation of the cardiac myocyte β1/β2
adrenergic-receptor is a potent contributor to myocardial disease. By
contrast, β3-receptor stimulation protects the heart from both hyper-
trophy and failure [1,2].β3-AR expression is expressed at very low levels
in the normal heart, but increases with pathophysiological conditions
(e.g. diabetes, hypertrophy, heart failure) unlike β1/β2-AR [3,4]. β3-AR
can be stimulated by high levels of catecholamines and is associated
with a countering negative inotropic effect mediated by inhibitorycense.
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as a physiological “brake” to protect the heart from sympathetic over-
drive [1]. β3-AR-mediated responses are maintained despite sustained
hyper-sympathetic activity because β3-AR lacks phosphorylation sites
for PKA and beta-AR kinase (βARK) that induce receptor desensitization
[7–9]. With heart failure, β3-AR signaling can depress contractility and
heart rate, but it also provides cardiac protectionmaking it an intriguing
therapeutic target.
The negative inotropic effect of β3-AR stimulation involves NOS/NO
signaling [2,5,10,11], and while it was initially thought to be due to en-
dothelial NOS (eNOS), new data has shown that neuronal NOS (nNOS)
also plays a key role [12–15]. In mice with nNOS genetically deleted or
acutely inhibited, β3-AR-dependent cardiac protection, NO generation,
and NOS downstream signaling are lacking in failing mouse myocardi-
um [10,11]. Napp et. al reported increased β3-AR-stimulated NO gener-
ation that was independent of eNOS in failing human hearts [16], also
supporting a role of other NOS isoforms. Myocytes express both eNOS
and nNOS, and recent studies have revealed the importance of nNOS
to cardiac calcium cycling and contractility [17,18]. Similar to eNOS,
nNOS activity can be modiﬁed by post-translational modiﬁcations
(PTMs) at speciﬁc residues. Phosphorylation at Ser1412, analogous to
Akt-dependent phosphorylation site of eNOS-Ser1177 enhances nNOS
activity [19]. By contrast, phosphorylation at Ser847, located on the
Ca2+-Calmodulin binding domain, inhibits nNOS [19]. As the β3-AR is
known to couple toGi/o- andAkt-dependent signaling, we hypothesized
that these PTMs may mediate the protective impact of β3-AR stimula-
tion in countering myocyte stress.
2. Methods
2.1. Cell culture
Neonatal Rat Ventricular Cardiomyocytes (NRVMs) were isolated
from 2 to 4 days old neonatal Sprague–Dawley pups (Taconic Farms,
Hudson, NY). Hearts were removed and placed into Krebs buffer
containing collagenase and trypsin. Isolated myocytes were plated
and incubated in DMEM with 10% FBS at 37 °C. Cells were stimulated
with BRL-37344 (Tocris, Bristol, UK). Prior to BRL administration cells
were pretreated with endothelin-1(ET-1) or norepinephrine (NE)
(Sigma-Aldrich, St. Louis, MO).
2.2. Pressure-overload model
Nine C57BL/6J male mice (9–10 weeks old, Jackson Laboratory, Bar
Harbor, ME) were arbitrarily divided into 3 groups. Two-thirds of the
mice underwent transverse aortic constriction (TAC) to induce cardiac
hypertrophy andheart failure via pressure overload,while the remaining
one-third had a sham procedure. Half of the TACmice were treated with
BRL (Tocris Bioscience, Ellisville, MO) at 0.1 mg/kg/day via osmotic
mini-pumps (Alzet Inc., Cupetino, CA) which were subcutaneously im-
planted one day post-TAC, as previously described [10].
2.3. Quantitative PCR
RNA was extracted from cells using Trizol Reagent and cDNA syn-
thesized. PCR reactions were analyzed using Taqman master mix,
β3-AR- and β-actin-speciﬁc probes, and GeneAmp 7900 sequence de-
tection system (Applied Biosystems, Foster City, CA).
2.4. Radiolabeled NOS activity assay
NOS calcium-dependent activity was determined from cellular ly-
sates by measuring C14 arginine to citrulline conversion (assay kits
from Cayman Chemical, Ann Arbor, MI) as previously described [2].2.5. Lucigenin-enhanced chemiluminescence
Myocardial superoxide was assayed by lucigenin-enhanced chemi-
luminescence. Cells were lysed and equilibrated in 1× Cell Lysis Buffer
(Millipore, Billerica, MA). After soniﬁcation, the lysates were added to
a low concentration of lucigenin-solution (5 μM) with 150 μM NADPH
to alleviate artifacts [20]. Baseline and maximum lucigenin-enhanced
chemiluminescent signal were detected by a liquid scintillation counter
(LS6000IC, Beckman Instruments, Fullerton, CA), with data reported as
counts per minute per milligrams of protein after background subtrac-
tion (cpm/mg) [21].
2.6. Western blotting
Cell andmyocardial lysateswere subjected to SDS-PAGE andproteins
were electrophoretically transferred to a nitrocellulose membrane as
previously described. Themembraneswere then exposed to primary an-
tibodies overnight at 4 °C. Antibody against phospho-nNOS-Ser847 was
purchased from Abcam (1:1000, Cambridge, MA) and anti-phospho-
nNOS-Ser1412 was a gift from K.J. Hurt (1:5000, UC-Denver). Anti-Myc
(1:5000), anti-nNOS (1:1000), anti-eNOS (1:1000), and anti-phospho-
eNOS-Ser1177 and−114 (1:1000) were purchased from Cell Signaling
(Boston, MA). Immunoreactive proteins were then incubated with the
peroxidase-linked secondary antibody (GE Healthcare, Piscataway, NJ)
for 1 h at room temperature, afterwards visualized by Thermo Scientiﬁc
Pierce Enhanced Chemiluminescence Western Blotting Substrate kit
(Rockford, IL).
2.7. cGMP
After treatment, cardiac myocytes were lysed with 0.1 M HCL and
centrifuged to pellet cellular debris. Supernatant was saved and
assayed using the acetylated format of the cGMP complete ELISA Kit
(Enzo Life Sciences, Farmingdale, NY).
2.8. Co-IP
Myocardial lysates were precipitated with afﬁnity-puriﬁed rabbit
anti-recombinant nNOS antibody. Antibody–protein complexes were
collected by Immobilized Protein A/G (Pierce) and eluted by boiling in
Laemmli sample buffer containing β-mercaptoethanol. The samples
were subjected to SDS-PAGE as described in the Western blotting
section.
2.9. Data analysis
The data presented is representative of at least three separate ex-
periments yielding similar results. Intensity of the immunoblot bands
were measured by UN-SCAN-IT gel Automated Digitizing System Ver-
sion 5.1. Counts per minute (cpm) detected from NOS activity and O2−
assays were measured by the LS6000IC liquid scintillation counter.
Data was analyzed with Prism 5.0 statistical program software using
one- or two-way analysis of variance (ANOVA) followed by Tukey
or Bonferroni post-test analysis where appropriate. Signiﬁcance was
shown at *p b 0.05.
3. Results
3.1. Cardiac myocyte hypertrophy augments β3-AR expression
Prior studies have shown that sustained stimulation ofβ-AR receptors
results in augmentation of the β3-AR expression [4,22].We tested if sim-
ilar upregulation was coupled to alternative GCPR-stimuli — speciﬁcally
the Gq-coupled agonists ET-1 andNE. NRVMswere exposed to either ag-
onist for 48–72 h, which resulted in a 40–60% increase in myocyte size.
Co-incubation with β3-AR agonist BRL-37344 (75 nM) reduced this
10 V.L. Watts et al. / Journal of Molecular and Cellular Cardiology 62 (2013) 8–17signiﬁcantly in both cases (Figs. 1A, B). With either Gq stimulant, β3-AR
mRNA expression rose (123.0 ± 1.7% ET-1, 131.4 ± 1.4% NE, both
P b 0.05). For simplicity, the subsequent experiments were conducted
using NE.
3.2. BRL restores NOS activity and attenuates superoxide generation via a
nNOS dependent mechanism
NE pre-treatment for 72 h induced marked suppression of NOS ac-
tivity in NRVMs. This was reversed by subsequent addition of BRL over
a 2-hour period, still in the presence of NE (Fig. 2A, left). The peak in-
crease was observed after 45 min, essentially restoring NOS activity to
normal basal levels (Fig. 2A, right). BRL had no signiﬁcant effect on
NOS activity in non-hypertrophied (non-stimulated) controls (Fig. 2A).
The fall in NOS activity with NE-pretreatment was accompanied by a re-
ciprocal rise in superoxide formation (Fig. 2B). BRL had a marked and
rapid effect on O2− production, reducing it by >70% within 10 min
(Fig. 2B, left, right shows summary data after 45 min). To test the im-
portance of nNOS to the total NOS activation, cells pre-treated with NE
were subsequently exposed to BRL in the presence or absence of the
nNOS-speciﬁc inhibitor, LVNIO. LVNIO treated cells showed a marked
reduction in BRL-enhanced NOS activity (Fig. 2C) and reduction in O2−.
In addition, BRL increased cGMP levels via an nNOS dependent mecha-
nism (Supplemental ﬁgure). This supports an important role of nNOS
in β3-mediated myocyte signaling.
3.3. BRL mediates post-translational modiﬁcation of nNOS and eNOS
The time-course of BRL-induced modiﬁcation of both NOS activity
and O2− modulation was most compatible with post-translational
changes of existing protein. To test this, we examined nNOS phosphory-
lation at Ser1412 and Ser847, sites of activation anddeactivation, respec-
tively [19]. BRL induced a 1-fold increase in Ser1412 phosphorylation
and virtually complete dephosphorylation at Ser847 (Fig. 3A), both con-
sistent with enhanced nNOS activity and reduced O2− production after
45 min. eNOS phosphorylation was also modiﬁed by BRL. The negative
regulatory site at Ser114 became phosphorylated over 45 min, whileFig. 1. Norepinephrine and ET-1 induced hypertrophy and β3-AR expression in isolated NR
72 h. A–B.) Cell surface area was determined by phase contrast microscopy. C.) β3-AR mRN
vs. basal; #p b 0.05 vs. respective agonist control in immunostaining experiment; and #p bthe stimulatory residue, Ser1177, remain unchanged (Fig. 3B). These
are consistent with reduced eNOS activation, opposite to that observed
for nNOS.
3.4. nNOS phosphorylation plays a key role in β3 signaling in vivo
To further test if BRL modulation of nNOS residue phosphorylation
was relevant in vivo, mice were subjected to transverse aortic con-
striction (TAC) [10] for 21 days with or without concomitant treat-
ment with BRL (0.1 mg/kg/day). We previously demonstrated that
BRL rescues the myocardium from TAC-induced heart failure and
NO reduction via an nNOS dependent manner [10]. In this study,
TAC induced a 40% increase in Ser847 phosphorylation over sham
control, and this was reversed by BRL, mimicking the in vitro ﬁndings
(Fig. 4A). There was also a trend for increased Ser1412 phosphoryla-
tion with TAC, and a signiﬁcant rise, with BRL treatment as compared
with sham control (Fig. 4B). Thus, BRL-induced nNOS PTMs are simi-
larly observed in a relevant in vivo model.
3.5. BRL-induced NOS activity and O2 levels are altered by nNOS
phosphomimetic mutants
To further investigate the relation between β3-regulated nNOS phos-
phorylation and both NOS activation and O2 suppression, myocytes were
infected with Sindbis viruses encoding for a c-myc-tagged site-mutated
nNOS with either Ser1412A, Ser847A, or Ser1412D, Ser847D (Fig. 5A).
This provided either phosphomimetic (aspartate, D) or silenced (alanine,
A)mutants [14]. Virus expressing green-ﬂuorescent protein (GFP) served
as negative controls. GFP viral constructs displayed an increased NOS ac-
tivity at baseline when compared to prior experiments with non-viral
infected cells. Nevertheless, BRLwas consistent in increasingNOS activity
by at least 55% from baseline in infected cells. BRL-dependent NOS activ-
ity was attenuated in cells expressing Ser847D or Ser1412A (enhancing
the negative regulating site, or blocking the activation site, respectively).
This indicates that β3-AR NOS activation is dependent upon PTM. The al-
ternative Ser847A mutant had no effect on BRL-induced NOS activity as
might be predicted, while Ser1412 mutant enhance NOS activity atVMs. Cells were treated with or without ET-1 (100 nM) for 48 h, and NE (100 mM) for
A expression was measured by qPCR, and normalized to baseline expression. *p b 0.05
0.05 vs. ET-1 in qPCR experiment.
Fig. 2. BRL restores NOS activity and suppresses hypertrophy-induced superoxide generation via a nNOS-dependent manner in hypertrophied cardiomyocytes. Cells were stimu-
lated for 45 min with BRL in the presence or absence of 72 h NE pretreatment, or LVNIO, nNOS inhibitor. Hypertrophied cells were stimulated at indicated time points to measure
A.) NOS activity, B.) superoxide generation in the absence or C–D.) presence of LVNIO. NOS activity was measured by 14C arginine to citrulline conversion and superoxide was mea-
sured by Lucigenin Assay. Data is presented as mean ± SEM for 3–6 experiments. *p b 0.001 vs. hypertrophied control; #p b 0.05 vs. LVNIO treated.
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decline in O2− (Fig. 5C). Unexpectedly, however, this was not observed
with the Ser1412A mutant. This suggests that β3-AR regulation of O2. is
dissociable from its activation of nNOS, and is linked to dephosphoryla-
tion of Ser847 and not Ser1412 phosphorylation.
3.6. BRL-induced nNOS-phosphorylation of Ser1412 is Akt-dependent
Previous studies have shown that nNOS phosphorylation of Ser1412
is Akt dependent [19,23]. Thus, we tested if the selective Akt-inhibitor
(Akt-i) could also prevent BRL modulation of nNOS activity. Following
BRL stimulation, hypertrophied myocytes treated with Akt-i showed
a signiﬁcant decrease in Ser1412 phosphorylation (Fig. 6A) but no
change in Ser847 phosphorylation (Fig. 6B) as compared to controls,accompanied by a 50% reduction in BRL-stimulated NOS activity
(Fig. 6C). However, the antioxidant response to BRL was unaltered by
Akt-i (Fig. 6D). In our in vivo studies we witnessed an increase in
nNOS–Akt interaction, as assessed by co-immunoprecipitation, in TAC
and TAC + BRL animals (Fig. 6E). This correlated with the increase in
Ser1412 phosphorylation seen in Fig. 4B. Interestingly, we observed no
change in Akt phosphorylation in isolated cells or heart extracts (data
not shown).
3.7. Gi/o inhibition alters β3-regulated nNOS phosphorylation, NOS activity,
and superoxide generation
β3-AR has been shown to signal eNOS via Gi/o in the ventricular
myocardium [24], however a role in nNOS stimulation has not been
Fig. 3. BRL alters phosphorylation of nNOS and eNOS in hypertrophied cardiomyocytes. Cells were stimulated for 45 min with BRL in the presence or absence of 72 h NE pretreat-
ment. Cells were stimulated at indicated time points to measure A.) nNOS-Ser1412 and -Ser847, and B.) eNOS-Ser1177 and -Ser114 phosphorylations. Phosphorylation was mea-
sured by Immunoblot analysis with phosphospeciﬁc antibodies. Data is presented as mean ± SEM for 3–6 experiments. *p b 0.05 vs. basal.
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Fig. 4. BRL administration alters nNOS phosphorylation in mice myocardium after pressure overload. C57BL/6J mice underwent 3-weeks of transverse aortic constriction (TAC) in
the presence or absence of BRL administration (0.1 mg/kg/day). Left ventricular myocardium was homogenized and probe against phospho-speciﬁc antibodies for A.) nNOS-Ser847
and B) Ser1412. Phosphorylation was measured by western blot analysis. Data is presented as mean ± SEM for three experiments. *p b 0.05 vs. SHAM; #p b 0.05 vs. TAC-BRL.
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Gαi/o signaling displayed a marked decline in BRL-induced S1412
phosphorylation, and signiﬁcant increases in S847 phosphorylation
(Figs. 7A–B). PTX treatment also resulted in blunted BRL-stimulated
NOS activity and its antioxidant effects (Figs. 7C–D).4. Discussion
While basal β3-AR expression and response to stimulation in the
heart is low to undetectable [4,10], growing evidence supports its
role in cardiac pathophysiological disorders where levels rise and sig-
naling becomes signiﬁcant [4,13,25,26]. Furthermore, recent data has
shown that genetic deletion of the pathway or its stimulation by se-
lective agonists can respectively worsen or improve the pathological
response to cardiac stress remodeling [2,10]. This modulation in the
diseased heart involves an interaction between the β3-AR and nNOS
[10,11]. In the current study, we provide novel evidence that the
nNOS modulation occurs rapidly, and involves phosphorylationFig. 5. nNOS phosphomimetic mutants alter BRL-induced NOS activity and superoxide su
Myc-tagged Sindbis viruses encoding an aspartate (D) or alanine (A) site-mutation for Ser
using Immunoblot analysis with antibodies against Myc protein. B.) NOS activity was me
Lucigenin Assay. GFP Sindbis virus was used to deﬁne basal levels of transformation. Data is
#p b 0.05 vs. GFP baseline.changes at two residues, Ser1412 and Ser847, one enhancing and
the other depressing nNOS activity (Fig. 8). Corresponding antioxi-
dant effects from β3-AR are also observed and shown linked to the
altered Ser847 phosphorylation in nNOS. In addition to revealing
a mechanistic link between β3-AR myocyte modulation and nNOS
activity, these results are the ﬁrst evidence of a role for nNOS
phosphorylation changes and myocyte-NO and ROS generation in
hypertrophied cells.4.1. β3-Agonism restores NOS activity and decreases ROS generation via
myocardial nNOS rather than eNOS
Activation of the β3-AR pathway in the ventricular myocardium is
accompanied by decreased contractility in humans and rodents due to
β3-AR's ability to generate NO via NOS signaling downstream of Gi/o ac-
tivation [10,11,16,24]. Negative inotropy from the β3-AR agonist, BRL, is
inhibited by both NO and non-selective NOS inhibitors and can be re-
versed by an excess of the substrate for NO production, L-arginine [24].ppression in hypertrophied cardiomyocytes. Hypertrophied cells were infected with
847 or Ser1412 for 24 h prior to 45 min BRL treatment. A.) Infection was determined
asured by 14C arginine to citrulline conversion and C.) superoxide was measured by
presented as mean ± SEM for 3–6 experiments. *p b 0.05 vs. respective viral control.
Fig. 6. Akt inhibition blocks β3-AR-induced NOS activity and Ser1412 phosphorylation in hypertrophied cardiomyocytes. Cells were stimulated for 45 min with BRL in the presence
or absence of Akt-i, Akt inhibitor, after NE pretreatment. Phosphorylation, NOS activity and superoxide were measured by A–B.) immunoblotting, C.) 14C arginine to citrulline con-
version, and D.) lucigenin assay, respectively. E.) Left ventricular myocardium was homogenized and immunoprecipitated with anti-nNOS then probed with anti-Akt. Data is
presented as mean ± SEM for three experiments. p b 0.05 vs. basal; #p b 0.05 vs. Akt-i + BRL group.
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β3-AR-induced NO generation was eNOS [2,24,27,28], recent studies
have suggested differently. In human failing left ventricularmyocardium,
Napp et al. observed that BRL was capable of inducing NO-dependent
negative inotropy even if myocardial eNOS was inactivated, suggesting
that another NOS isoform or paracrine signaling from endothelial eNOS
was involved [16]. In failing mouse hearts, we found that β3-agonism
led to nNOS-dependent protection of left ventricular function, while in-
ducing eNOS deactivation via Ser114 phosphorylation [10] Furthermore,
Aragon et al. demonstrated that the dual β1-blocker and β3-agonist,
nebivolol, failed to reduce myocardial ischemic-reperfusion infarct size
in nNOS−/− animals as comparedwithWT [11]. This refocused attention
on β3-AR interaction with nNOS.
In the current study, we established a hypertrophy-pre-stimulation
cell model, capable of activating β3-AR expression and myocyte hyper-
trophy, depressing NOS activity while concomitantly enhancing super-
oxide generation. The model facilitated the analysis of β3-AR and
nNOS signaling without interference by vascular cells. The ﬁnding that
BRL stimulation reversed these cellular responses,whichwas prevented
by co-treatment with the nNOS inhibitor LVNIO, strongly supports this
isoform to be a determining factor of pathophysiologies in myocytes.These data further show that nNOS is acting not only as an important
β3-AR modulated source of NOS activity, but also as a regulator of ROS
induced by NE-stimulation. The source of ROS is not necessarily NOS it-
self, however. This was suggested by our studies in the S1412Amutants
that inhibited the BRL-induced augmentation of NOS activity, yet still
exhibited an antioxidant effect from β3-AR stimulation. Other studies
have also suggested that myocardial nNOS can interact speciﬁcally
with xanthine oxidase reductase (XOR) derived O2− [15,29,30], thought
to be primarily due to co-localization at the sarcoplasmic reticular
membrane. More recently, Idigo et al. showed that XOR inhibition re-
stores β3 negative inotropy as well as eNOS coupling in nNOS−/−
myocytes [15]. Whether and how nNOS may suppress other sources of
ROS, such as from NADPH oxidases or monoamine oxidases, remains
to be determined.
In hypertrophied myocytes, an increase in β3-AR mRNA was ob-
served,which is consistentwith literature that demonstrates a functional
signiﬁcance of β3-AR under pathophysiological conditions [3,31].
Though myocyte β3-AR levels are modest, the relative effect may be
magniﬁed due to the ampliﬁcation of downstream signaling pathways
in addition to concomitant down-regulation of β1-AR, which has been
demonstrated in the setting of hypertrophy [3,31]. Under normal
Fig. 7. Gi/o inhibition blocks β3-induced Ser1412 phosphorylation, NOS activity, and superoxide suppression while partially restoring Ser847. Cells were pretreated with NE for 72 h
and stimulated for 45 min with BRL in the presence or absence of Pertussis Toxin, Gi/o inhibitor. Phosphorylation was detected with A.) Ser1412 and B) nNOS-Ser847
phospho-speciﬁc antibodies. C.) NOS activity and D.) superoxide generation were measured by 14C arginine to citrulline conversion and Lucigenin assay, respectively. Data is
presented as mean ± SEM for three experiments. *p b 0.05 vs. basal; #p b 0.05 vs. BRL alone.
15V.L. Watts et al. / Journal of Molecular and Cellular Cardiology 62 (2013) 8–17conditions cardiac β1 to β3 ratio is 8:1 as compared with 2:1 during
cardiomyopathies [31].
4.2. Phosphorylation of nNOS provides differential regulation of downstream
β3-signaling
Post-translational modiﬁcation plays an important role in the func-
tionality of NOS isoforms [10,19,32]. nNOS undergoes post-translational
modiﬁcation via phosphorylation [33]. We found β3-agonism inducedFig. 8. Proposed signal transduction cascade by which β3-AR activation leads to NOS
signaling and ROS scavenging in cardiac myocytes.nNOSphosphorylation at Ser1412, a positive regulatory site, and dephos-
phorylation at site Ser847 — a negative modulator. While some insight
into nNOS — PTMs has been reported from neuroscience, nothing has
been previously reported in cardiac myocytes or hearts. In neurons,
phosphorylation of Ser1412 is required for nNOS-dependent NO produc-
tion induced by N-methyl-D-aspartate (NMDA) receptors, estradiol, and
adrenomedullin [33,34]. Further, inhibition of AngII in spontaneous hy-
pertensive rats increases nNOS-Ser1412 phosphorylation in neurons of
the nucleus tractus solitarii (NTS) [35]. In myocytes, nNOS is thought
to be constitutively activated and regulating SR-calcium cycling [36],
though the level of basal S1412 phosphorylation is low, so this PTM
would seemmore important to stress-induced activation.
The current study used both gain and loss of phospho-function
mutations to examine their respective roles. Besides ﬁnding correla-
tions between the time-course of enhanced NOS activity and these
PTMs following exposure to BRL, we show their individual contribu-
tion to both enhanced NOS activity and ROS modulation. Analogous
to the eNOS positive regulatory site, nNOS-Ser1412 has been ob-
served to be primarily PI3K/Akt dependent [19,33], although Yen et
al. suggested a possible role for PKA as well [34]. The Akt-inhibitor
studies, however showed that this is likely the primary targeting ki-
nase for this site PTM in myocytes, at least as coupled to β3-AR acti-
vation. Here again, the data showed a selective inﬂuence of this
phosphorylation site on NOS activity, but not on O2− modulation,
supporting alternative changes in nNOS for the latter.
Dephosphorylation at Ser847 also increases nNOS activity and as-
sociated NO generation [19,34]. This residue is located in the Ca2+/
Calmodulin binding domain of the nNOS enzyme, and phosphorylat-
ed Ser847 blocks Ca2+/Calmodulin binding which is necessary for
16 V.L. Watts et al. / Journal of Molecular and Cellular Cardiology 62 (2013) 8–17nNOS activation [37]. In murine cerebellum and hippocampus, spinal
cord injury and forebrain ischemia impair nNOS/NOS signaling path-
ways through Ser847 phosphorylation via Ca2+/Calmodulin Kinase II
modulation [38,39]. Our analysis has clariﬁed that in heart, modiﬁcation
of this site is coupled to bothNOgeneration and the capacity of nNOS ac-
tivity to suppress ROS signaling. Further, we show that this is uncoupled
from Akt, but is linked to a Gi/o-activation cascade. This could occur by
Gi/o-coupled phosphatase activation or suppression of the required ki-
nase. Potential candidates are PP1/PP2A, and PP2B (calcineurin) which
enhance hippocampal NMDA-mediated nNOS-Ser847 phosphorylation
in an ischemia model [34]. However, others have found a decline in
phosphorylation following PP1/PP2A and PP2B inhibition in rat cortical
neurons [35], so the precise targeting is unclear.
5. Conclusion
We conclude that myocardial β3-mediated NOS signaling is depen-
dent upon alterations in phosphorylation of nNOS at sites Ser1412 and
Ser847 in cardiomyocytes under pathophysiological conditions. In addi-
tion,we conclude thatβ3-mediatednNOS-dependent ROS scavenging is
solely dependent upon dephosphorylation of negative regulatory site
Ser847. To our knowledge this is the ﬁrst study to demonstrate a role
for nNOS phosphorylation as a key mediator in cardiac signaling, in ad-
dition to β3-AR protective signaling cascade. These results contribute
signiﬁcantly to our understanding of the negative inotropic properties
of myocardial β3-AR at the cellular level during cardiac sympathetic
overstimulation, and will ultimately aid in drug discoveries that target
the molecular mechanisms associated with cardiac hypertrophy and
heart failure.
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